Stockscreener 앱 받기
0.1994
46.62%
0.0634
시장 영업 전:
.27
0.0706
+35.41%
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Leerink upgrades Gossamer Bio stock rating on FDA feedback By Investing.com - Investing.com Canada
GOSS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver Quantitative
Gossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million - TradingView
Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom - TechStock²
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Benzinga
GOSS, Gossamer Bio Updates on Seralutinib and Strategic Developm - GuruFocus
GOSS: Key Regulatory and Corporate Developments Announced - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Gossamer Bio shares jump after FDA update and seralutinib rights return - Yahoo Finance
Gossamer Bio stock surges 25% on FDA regulatory update - Investing.com
Why is Gossamer Bio stock surging today? By Investing.com - Investing.com Canada
Gossamer Bio plans September NDA submission for seralutinib By Investing.com - Investing.com Nigeria
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business Wire
Gossamer Bio Inc (GOSS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gossamer Bio Inc (GOSS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
$Gossamer Bio (GOSS.US)$ mood today - Moomoo
Gossamer Bio Inc (GOSS) Balance Sheet - TradingKey
Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
$Gossamer Bio (GOSS.US)$ - Moomoo
GOSS|Gossamer Bio Inc|Price:0.147|Chg%:+0.011 - TradingKey
Gossamer Bio Inc (GOSS) Income Statement - TradingKey
Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gossamer Bio, Inc. Revenue Breakdown – NASDAQ:GOSS - TradingView
Gossamer Bio, Inc. Revenue Breakdown – SWB:4GB - TradingView
GOSS|Gossamer Bio Inc|Price:0.136|Chg%:-0.006 - TradingKey
Form 13D/A Gossamer Bio For: 24 July By Investing.com - Investing.com Nigeria
Gossamer Bio Inc (GOSS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ETFs Investing in Gossamer Bio, Inc. Stocks - TradingView
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio stock edges higher as trial setbacks and restructuring reshape outlook - Ad-hoc-news.de
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio(GOSS) Stock Options Chain | Quotes & News - Moomoo
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Remains KeyPost-Announcement Reaction - dars.gov.et
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - AOL.com
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Price to earnings forward of Gossamer Bio, Inc. – MUN:4GB - TradingView
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio (GOSS) Income Statement & Earnings - Moomoo
2026-07-09 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Shareholders to Learn More About the Investigation | NDAQ:GOSS | Press Release - Stockhouse
GOSS Investor AlertGossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - AOL.com
Gossamer Bio (GOSS) Q1 2025 earnings summary - Quartr
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes - Global Legal Chronicle
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - AOL.com
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - AOL.com
Gossamer Bio focuses on respiratory pipeline as markets weigh biotech valuations - Ad-hoc-news.de
GOSSGossamer Bio Inc Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Price to earnings forward of Gossamer Bio, Inc. – DUS:4GB - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
GOSS Should I Buy - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Shareholders to Connect - ACCESS Newswire
Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes - Yahoo Finance
D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):